Barber A - Search Results

1

Human NK cell IFN-gamma production is regulated by endogenous TGF-beta.

Meadows SK, Eriksson M, Barber A, Sentman CL. Meadows SK, et al. Among authors: barber a. Int Immunopharmacol. 2006 Jun;6(6):1020-8. doi: 10.1016/j.intimp.2006.01.013. Epub 2006 Feb 17. Int Immunopharmacol. 2006. PMID: 16644489

2

NK cell receptors as tools in cancer immunotherapy.

Sentman CL, Barber MA, Barber A, Zhang T. Sentman CL, et al. Among authors: barber ma, barber a. Adv Cancer Res. 2006;95:249-92. doi: 10.1016/S0065-230X(06)95007-6. Adv Cancer Res. 2006. PMID: 16860660 Review.

3

NKG2D receptor regulates human effector T-cell cytokine production.

Barber A, Sentman CL. Barber A, et al. Blood. 2011 Jun 16;117(24):6571-81. doi: 10.1182/blood-2011-01-329417. Epub 2011 Apr 25. Blood. 2011. PMID: 21518928 Free PMC article.

4

Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.

Barber A, Meehan KR, Sentman CL. Barber A, et al. Gene Ther. 2011 May;18(5):509-16. doi: 10.1038/gt.2010.174. Epub 2011 Jan 6. Gene Ther. 2011. PMID: 21209626 Free PMC article.

5

Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.

Zhang T, Barber A, Sentman CL. Zhang T, et al. Among authors: barber a. Cancer Res. 2006 Jun 1;66(11):5927-33. doi: 10.1158/0008-5472.CAN-06-0130. Cancer Res. 2006. PMID: 16740733

6

Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.

Barber A, Zhang T, DeMars LR, Conejo-Garcia J, Roby KF, Sentman CL. Barber A, et al. Cancer Res. 2007 May 15;67(10):5003-8. doi: 10.1158/0008-5472.CAN-06-4047. Cancer Res. 2007. PMID: 17510432

7

Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.

Zhang T, Barber A, Sentman CL. Zhang T, et al. Among authors: barber a. Cancer Res. 2007 Nov 15;67(22):11029-36. doi: 10.1158/0008-5472.CAN-07-2251. Cancer Res. 2007. PMID: 18006849

8

Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer.

Barber A, Zhang T, Sentman CL. Barber A, et al. J Immunol. 2008 Jan 1;180(1):72-8. doi: 10.4049/jimmunol.180.1.72. J Immunol. 2008. PMID: 18097006

9

Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity.

Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, Elgueta R, Wang L, Nesbeth Y, Durant Y, Gewirtz AT, Sentman CL, Kedl R, Conejo-Garcia JR. Cubillos-Ruiz JR, et al. Among authors: barber a. J Clin Invest. 2009 Aug;119(8):2231-44. doi: 10.1172/JCI37716. Epub 2009 Jul 13. J Clin Invest. 2009. PMID: 19620771 Free PMC article.

10

Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.

Barber A, Sentman CL. Barber A, et al. J Immunol. 2009 Aug 15;183(4):2365-72. doi: 10.4049/jimmunol.0900721. Epub 2009 Jul 22. J Immunol. 2009. PMID: 19625653 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

721 results

Search Page

Filters